SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Twist Bioscience has shown revenue growth from $54.4m in 2019 to potentially >$300m in 2024, but continues to post losses. Despite a diverse customer base and innovative synthetic DNA technology, ...
Twist Bioscience reported solid Q1 FY25 results, although this was insufficient to drive the company's share price higher. The demand environment remains challenging, and Trump's election has created ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback